EP4090736A4 - Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3 - Google Patents

Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3 Download PDF

Info

Publication number
EP4090736A4
EP4090736A4 EP21738384.3A EP21738384A EP4090736A4 EP 4090736 A4 EP4090736 A4 EP 4090736A4 EP 21738384 A EP21738384 A EP 21738384A EP 4090736 A4 EP4090736 A4 EP 4090736A4
Authority
EP
European Patent Office
Prior art keywords
dnase1l3
dnase1
ameliorating
deficiency
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21738384.3A
Other languages
German (de)
English (en)
Other versions
EP4090736A1 (fr
Inventor
Paul STABACH
Demetrios Braddock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP4090736A1 publication Critical patent/EP4090736A1/fr
Publication of EP4090736A4 publication Critical patent/EP4090736A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP21738384.3A 2020-01-11 2021-01-11 Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3 Pending EP4090736A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959932P 2020-01-11 2020-01-11
PCT/US2021/012990 WO2021142456A1 (fr) 2020-01-11 2021-01-11 Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3

Publications (2)

Publication Number Publication Date
EP4090736A1 EP4090736A1 (fr) 2022-11-23
EP4090736A4 true EP4090736A4 (fr) 2024-02-21

Family

ID=76788354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21738384.3A Pending EP4090736A4 (fr) 2020-01-11 2021-01-11 Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3

Country Status (10)

Country Link
US (2) US20230062096A1 (fr)
EP (1) EP4090736A4 (fr)
JP (1) JP2023510781A (fr)
KR (1) KR20220152196A (fr)
CN (1) CN115066494A (fr)
AU (1) AU2021205976A1 (fr)
BR (1) BR112022013173A2 (fr)
CA (1) CA3166299A1 (fr)
IL (1) IL294114A (fr)
WO (1) WO2021142456A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
AU2021288567A1 (en) * 2020-06-08 2023-02-09 Yale University Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072741A2 (fr) * 2002-02-26 2003-09-04 Southern Illinois University Regulation therapeutique de l'activite de desoxyribonuclease 1-3
WO2015066550A1 (fr) * 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Fusions nucléase-albumine à visée thérapeutique et procédés associés
WO2019036719A2 (fr) * 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. Enzymes dnase génétiquement modifiées et leur utilisation en thérapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250185A1 (en) * 2003-12-12 2005-11-10 Murphy Andrew J OGH fusion polypeptides and therapeutic uses thereof
EP3449933A1 (fr) * 2011-04-29 2019-03-06 University of Washington Compositions à base de nucléase thérapeutique et procédés associés
MX355234B (es) * 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
EP3205719A1 (fr) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Lignées cellulaires pour la production de glycoprotéines recombinées avec des n-glycanes di-antennulaire, procédés d'utilisation de ces derniers et des glycoprotéines de recombinaison
HRP20240603T1 (hr) * 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimizirane fuzije binukleaze i postupci njihove upotrebe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072741A2 (fr) * 2002-02-26 2003-09-04 Southern Illinois University Regulation therapeutique de l'activite de desoxyribonuclease 1-3
WO2015066550A1 (fr) * 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Fusions nucléase-albumine à visée thérapeutique et procédés associés
WO2019036719A2 (fr) * 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. Enzymes dnase génétiquement modifiées et leur utilisation en thérapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AL-MAYOUF SULAIMAN M ET AL: "Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus", NATURE GENETICS, vol. 43, no. 12, 23 October 2011 (2011-10-23), New York, pages 1186 - 1188, XP093116111, ISSN: 1061-4036, Retrieved from the Internet <URL:http://www.nature.com/articles/ng.975> DOI: 10.1038/ng.975 *
DWYER MARY A ET AL: "Expression and characterization of a DNase I-Fc fusion enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 274, no. 14, 2 April 1999 (1999-04-02), pages 9738 - 9743, XP002697473, ISSN: 0021-9258, DOI: 10.1074/JBC.274.14.9738 *
MOUCHESS MARIA ET AL: "A rationally engineered DNase1-Fc fusion protein ameliorates autoimmune glomerulonephritis", THE JOURNAL OF IMMUNOLOGY, vol. 202, no. 1_Supplement, 1 May 2019 (2019-05-01), US, pages 132.4 - 132.4, XP093116114, ISSN: 0022-1767, Retrieved from the Internet <URL:https://journals.aai.org/jimmunol/article/202/1_Supplement/132.4/61766/A-rationally-engineered-DNase1-Fc-fusion-protein> DOI: 10.4049/jimmunol.202.Supp.132.4 *
See also references of WO2021142456A1 *

Also Published As

Publication number Publication date
CA3166299A1 (fr) 2021-07-15
AU2021205976A1 (en) 2022-07-07
CN115066494A (zh) 2022-09-16
JP2023510781A (ja) 2023-03-15
US20230416358A1 (en) 2023-12-28
EP4090736A1 (fr) 2022-11-23
US20230062096A1 (en) 2023-03-02
BR112022013173A2 (pt) 2022-09-13
KR20220152196A (ko) 2022-11-15
WO2021142456A1 (fr) 2021-07-15
IL294114A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
WO2022031847A3 (fr) Compositions et méthodes d&#39;inhibition de l&#39;expression de plp1
IL287032A (en) Preparations and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with disease-causing microorganisms
WO2008021210A3 (fr) Méthodes et compositions pour le traitement de troubles neurodégénératifs
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
WO2008054200A3 (fr) Utilisation de compositions nutritives pour empêcher des troubles
WO2008067121A3 (fr) Méthodes de traitement des troubles cognitifs et de la démence
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
EP4090736A4 (fr) Compositions et méthodes pour traiter, améliorer et/ou prévenir des maladies ou des troubles causés par ou associés à un déficit en dnase1 et/ou dnase1l3
WO2015143447A3 (fr) Méthodes de traitement de troubles neurologiques
WO2007114903A3 (fr) Traitements à la citrulline
EP3712264A8 (fr) Enzyme cystathionine bêta-synthase pour le traitement de l&#39;homocystinurie
WO2011075606A3 (fr) Variants de polypeptide hyperglycosylé et procédés d&#39;utilisation
EP3917622A4 (fr) Compositions et méthodes de traitement de troubles liés à l&#39;anxiété
EP3979985A4 (fr) Compositions et méthodes pour traiter des troubles du système nerveux central
WO2008157747A8 (fr) Utilisation d&#39;inhibition d&#39;exonucléase i dans des procédés de thérapie et de diagnostic de maladies neurodégénératives, de maladies oculaires et de troubles mitochondriaux
EP4188368A4 (fr) Compositions et méthodes de traitement de maladies et de troubles
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
WO2006079068A3 (fr) Compositions et methodes permettant d&#39;etudier et de traiter des maladies et des troubles inflammatoires
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2022010868A (es) Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.
EP3625248A4 (fr) Compositions et procédés pour le diagnostic et le traitement de maladies et de troubles associés au kcnj5 mutant
EP3986439A4 (fr) Compositions et méthodes utiles dans le traitement de maladies du cerveau
EP3968977A4 (fr) Compositions et méthodes contre les troubles affectifs induits par le stress et leurs symptômes associés
WO2008021432A3 (fr) Compositions et méthodes de traitement d&#39;états affectant le système nerveux
EP4103177A4 (fr) Compositions et méthodes pour le traitement et/ou la prévention de maladies oculaires

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220811

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

A4 Supplementary search report drawn up and despatched

Effective date: 20240124

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/22 20060101AFI20240118BHEP